⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
BACKGROUND: Options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes for surveillance and prophylactic mastectomy are incomplete. METHODS: We conducted a retrospective study of all women with a family history of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. The women were divided into two groups - high risk and moderate risk - on the basis of family history. A control study of the sisters of the high-risk probands and the Gail model were used to predict the number of breast cancers expected in these two groups in the absence of prophylactic mastectomy. RESULTS: We identified 639 women with a family history of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at moderate risk. The median length of follow-up was 14 years. The median age at prophylactic mastectomy was 42 years. According to the Gail model, 37.4 breast cancers were expected in the moderate-risk group; 4 breast cancers occurred (reduction in risk, 89.5 percent; P<0.001). We compared the numbers of breast cancers among the 214 high-risk probands with the numbers among their 403 sisters who had not undergone prophylactic mastectomy. Of these sisters, 38.7 percent (156) had been given a diagnosis of breast cancer. By contrast, breast cancer was diagnosed in 1.4 percent (3 of 214) of the probands. Thus, prophylactic mastectomy was associated with a reduction in the incidence of breast cancer of at least 90 percent. CONCLUSIONS: In women with a high risk of breast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the incidence of breast cancer.
Coeff. authors = avg(1.00, 1.00) = 1.00
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(1.00, 0.95) = 0.95← lowest dominates
Final coefficient : 0.95
Final score = 40.5/52.8 × 0.95 × 100 = 73/100
Overdiagnosis in cancer.
Welch HG — 2010 · Journal of the National Cancer Institute
Contrasted resultsPalbociclib and Letrozole in Advanced Breast Cancer.
Finn RS — 2016 · The New England Journal of Medicine
Contrasted resultsTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ — 2005 · The New England journal of medicine
Contrasted resultsOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson M — 2017 · The New England Journal of Medicine
Contrasted results5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally adva…
Gianni L — 2016 · The Lancet Oncology